UAB / UMN SPORE in Pancreatic Cancer

胰腺癌中的 UAB / UMN SPORE

基本信息

批准号：
8707193
负责人：
DONALD J. BUCHSBAUM
金额：
$ 216.2万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
2003
资助国家：
美国
起止时间：
2003-09-16 至 2017-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8707193
关键词：
Adenovirus Vector Advocacy Animal Model Biological Markers Biometry Chairperson Clinical Management Clinical Trials Data Development Diagnosis Disease Early Diagnosis Engineering Event Funding Genetic Genomics Goals Grant Guidelines Human Image Institution Joints Lead Magnetic Resonance Imaging Malignant neoplasm of pancreas Methods Minnesota Monoclonal Antibodies Morbidity - disease rate Morehouse School of Medicine Neoplasm Metastasis Operative Surgical Procedures Patients Phase I Clinical Trials Phase II Clinical Trials Population Proteomics Public Health Publications Recruitment Activity Research Research Personnel Resistance Resources Sampling Science Scientist Staging TNFRSF10B gene Techniques Therapeutic Agents Transgenic Animals Translations Treatment Efficacy Universities University of Alabama at Birmingham Cancer Center anticancer research cancer stem cell career development molecular pathology mortality mouse model neoplastic cell novel novel therapeutics patient population programs research and development tissue resource

项目摘要

Six years ago, our UAB SPORE in Pancreatic Cancer application was partially funded via a P-20 grant. With limited funding; our mini-SPORE was composed of 2 major projects, 3 Cores and a Developmental Research Program. During this initial funding period, translation of SPORE science resulted in two phase I trials, one Phase II trial and a novel MRI imaging trial. The investigators of the SPORE have 88 publications relating to SPORE projects or pancreatic cancer. The Developmental Research funding resulted in two major projects, Projects 1, & 4 in this renewal application and 2 awardees becoming Project co-leaders. Three years ago, Dr. Vickers (SPORE PI) became Chairman of Surgery at the University of Minnesota (UMN) and we restructured into a joint UAB/UMN SPORE in Pancreatic Cancer. The joint SPORE has functioned well and this proposal is our amended competitive renewal for full SPORE funding (PSO application). This proposal has 4 major projects: Project 1 is utilizing proteomic techniques in transgenic animal models to identify biomarkers that are predictive of early stage pancreatic cancer; Project 2 is a continuation project which is examining multiple methods to enhance the therapeutic efficacy of anti-DR5 monoclonal antibodies in pancreatic cancer animal models and patients; Project 3 is utilizing genomic and genetic data obtained from human pancreatic cancer (PCa) samples and observations from mouse models of PCa to understand the genetic events that drive metastasis and treatment resistance in this disease. These studies will lead to a phase I clinical trial; Project 4 is engineering novel conditionally replicative adenoviral vectors that target pancreatic cancer stem cell-like tumor cells for the treatment of metastatic pancreatic cancer. The four important and effective Cores are: 1) Administration; 2) Tissue Resource and Molecular Pathology; 3) Biostatistics; and 4) Clinical Management and Trials (Advocacy Sub-Core). We also request support for continuation of our Developmental Research and Career Development Programs which includes Morehouse School of Medicine and Tuskegee University. The application has strong institutional support from UAB and UMN, excellent pancreatic cancer populations and concurrence with federal guidelines.

六年前，我们的 UAB SPORE 在胰腺癌应用中的部分资金来自 P-20 拨款。资金有限；我们的迷你 SPORE 由 2 个主要项目、3 个核心和一个发展研究计划组成。在最初的资助期间，SPORE 科学的转化导致了两项 I 期试验、一项 II 期试验和一项新型 MRI 成像试验。 SPORE 的研究人员发表了 88 篇与 SPORE 项目或胰腺癌相关的出版物。发展研究资金导致了两个主要项目，即本续签申请中的项目 1 和项目 4，并且 2 名获奖者成为项目联合负责人。三年前，Vickers 博士 (SPORE PI) 成为明尼苏达大学 (UMN) 的外科主席，我们重组为联合 UAB/UMN SPORE 胰腺癌中心。联合 SPORE 运作良好，该提案是我们对 SPORE 全额资金（PSO 申请）的修订竞争性更新。该提案有 4 个主要项目：项目 1 是在转基因动物模型中利用蛋白质组学技术来识别预测早期胰腺癌的生物标志物；项目2是一个延续项目，正在研究多种方法来增强抗DR5单克隆抗体在胰腺癌动物模型和患者中的治疗效果；项目 3 正在利用从人类胰腺癌 (PCa) 样本中获得的基因组和遗传数据以及 PCa 小鼠模型的观察结果来了解驱动这种疾病转移和治疗耐药性的遗传事件。这些研究将进入一期临床试验；项目 4 正在设计新型条件复制腺病毒载体，靶向胰腺癌干细胞样肿瘤细胞，用于治疗转移性胰腺癌。四个重要且有效的核心是： 1) 管理； 2）组织资源与分子病理学； 3）生物统计学； 4) 临床管理和试验（宣传子核心）。我们还请求支持继续开展我们的发展研究和职业发展计划，其中包括莫尔豪斯医学院和塔斯基吉大学。该应用程序得到了 UAB 和 UMN 的强有力的机构支持、优秀的胰腺癌人群以及与联邦指南的一致。